Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.

Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the first patient has been dosed in the 12-month open-label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial.

Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) has today announced the first of several key appointments in the near term to advance PBT2 into late stage and pre-market clinical development of PBT2 as a treatment for Alzheimer’s and Huntington diseases.

Prana Biotechnology (ASX:PBT / NASDAQ:PRAN), a leading global developer of first-in-class treatments for neurodegenerative disease, has today provided an update on three clinical trials testing its proprietary drug, PBT2, in Alzheimer’s and Huntington’s diseases.

The top 10 list is selected by an independent panel each year to highlight compounds which address a large, unmet market, strong science and a diversity of indications. Other criteria include the potential for new opportunities beyond initial indications, multi-level partnering opportunities and a strong company behind the compound.

Principal Investigator, Dr James Duce from The University of Leeds, UK, will collaborate with Professor David Finkelstein of The Florey Institute of Neuroscience and Mental Health (FINMH) in Australia and Associate Professor Robert Cherny of FINMH and Prana’s Head of Research on the Study.

Prana Biotechnology today announced that it has received approval from the United States Food and Drug Administration (FDA) to start recruiting patients for the company's first clinical trial using PBT2 in patients with Huntington’s Disease (HD).

Prana Biotechnology today commented on three recent high profile scientific journal articles that the company believes provide support for Prana’s therapeutic strategy for treating neurodegenerative disease.

Prana Biotechnology today announced that the first patient has been dosed in the “IMAGINE Trial” - 12 month Phase II Imaging trial testing PBT2, the Company’s drug in development for Alzheimer’s Disease.

Prana Biotechnology today announced the publication in the journal PLoS ONE, of an article that strongly endorses PBT2’s potential to treat Alzheimer’s Disease. The paper, entitled “The Zinc Dyshomeostasis Hypothesis of Alzheimer’s Disease”1 presents an integrated explanation of the major pathological features of Alzheimer’s Disease, based upon a combination of new experimental data and mathematical modeling.